Cybin Inc CYBN CYBN, a clinical-stage biopharmaceutical company on the frontier of developing psychedelic-based therapies, provided updates on its ongoing clinical trials evaluating its proprietary deuterated molecules of a psilocybin analog known as CYB003, and CYB004 DMT.
The preliminary data was positive for both drug candidates. Both demonstrated efficacy and were well tolerated. See the full announcement here.
Learn more about Cybin:
This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice.
Featured photo by danilo.alvesd on Unsplash
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
